Tumor angiogenesis plays an important role in the development of cancer. Previously, we reported that hepatitis B X-interacting protein (HBXIP) functioned as an oncoprotein in breast cancer. However, the role of HBXIP in angiogenesis in breast cancer remains poorly understood. In the present study, we show that the oncoprotein HBXIP plays crucial roles in the event. We observed that the expression levels of HBXIP were positively correlated with those of fibroblast growth factor 8 (FGF8) or vascular endothelial growth factor (VEGF) in clinical breast cancer tissues. Then, we demonstrated that HBXIP was able to upregulate FGF8 through activation of its promoter involving direct binding to cAMP response element-binding protein (CREB) in breast cancer cells and thereby increased its secretion. Strikingly, we identified another pathway that HBXIP upregulated FGF8 and VEGF through inhibiting miRNA-503, which directly targeted 3′ untranslated region of FGF8 or VEGF mRNA in the cells. Moreover, we revealed that HBXIPinduced FGF8 could upregulate VEGF expression through activating phosphoinositide 3-kinase (PI3K)/Akt/hypoxia-inducible factor 1-alpha (HIF1α) signaling and increase its secretion. In function, matrigel angiogenesis assay and hemoglobin content analysis uncovered that HBXIP-enhanced FGF8/VEGF boosted tumor angiogenesis and growth in breast cancer in vitro and in vivo in a paracrine/autocrine manner. Thus, we conclude that HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. Our finding provides new insights into the mechanism of tumor angiogenesis in breast cancer. Therapeutically, HBXIP may serve as a novel target of tumor angiogenesis.
Introduction
Angiogenesis, the sprouting of new capillaries from preexisting blood vessels, is a vital process in physiologic and pathophysiologic conditions, including embryonic development, wound healing, atherosclerosis, diabetic retinopathy and tumor progression (1) . In cancer, the tumor microenvironment is composed of numerous cell types that influence tumor angiogenesis. Tumor cells modulate their microenvironment by releasing growth factors and cytokines to activate quiescent, normal cells surrounding them and trigger a cascade of events that rapidly becomes deregulated (2) .
One of the best characterized modulators of angiogenesis is the heparin-binding fibroblast growth factor (FGF), which contributes to autocrine and paracrine growth stimulation to regulate cell proliferation, survival, migration and differentiation during development and carcinogenesis (3, 4) . It has been reported that dysregulation of FGF signaling is associated with many developmental syndromes and human cancers (3, 5) . FGF8, originally isolated from the conditioned medium of an androgen-dependent mouse mammary carcinoma line (SC-3), plays a vital role in embryogenesis and organogenesis (6) . High frequency of FGF8 expression has been detected in clinical breast cancer tissues (7, 8) . FGF8b is the primary isoform detected in breast cancer (8) . Overexpression of FGF8b leads to increased tumor angiogenesis, growth and metastasis (9, 10) .
Vascular endothelial growth factor (VEGF), another best characterized modulator of angiogenesis, is essential for angiogenesis and metastatic growth in pathophysiology, which has been associated with poor prognosis in breast cancer (11, 12) . Its expression is modulated not only by many transcriptional factors and cytokines but also by several growth factors, such as transforming growth factor-β, epidermal growth factor, platelet-derived growth factor-BB and FGFs (12) (13) (14) (15) . Previous reports showed that VEGF and FGF system, acting through distinct receptor kinases, might function in a synergistic manner to enhance angiogenesis (16, 17) .
Mammalian hepatitis B X-interacting protein (HBXIP) is originally identified because of its interaction with the C terminus of the hepatitis B virus X protein (18) . It can collaborate with cytosolic survivin to control cell apoptosis and division (19) . HBXIP is also a regulator of centrosome dynamics and cytokinesis to mediate cell growth (20) . In addition, HBXIP is identified as a regulator component that is required for mTORC1 activation by amino acids (21) . Besides, HBXIP is involved in angiogenesis of hepatoma HepG2 cells (22) , but the molecular mechanisms are not well documented. Our group has reported that HBXIP is able to import into the nucleus in breast cancer cells and serves as a coactivator of transcriptional factors to promote cell proliferation and migration of breast cancer (23) (24) (25) (26) (27) . However, the role of HBXIP and its mechanism in promoting angiogenesis in breast cancer remain unclear.
In this study, we are interested in the role of HBXIP in angiogenesis in breast cancer. Our data show that HBXIP can markedly enhance angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. Our findings provide new insights into the mechanism of tumor angiogenesis in breast cancer.
Materials and methods
Cell culture, tissue specimen and oligonucleotides Human umbilical vein endothelial cells (HUVECs), SK-BR-3, MCF-7 and MCF-7-HBXIP (MCF-7 stably transfected with the HBXIP) cells were cultured in RPMI medium 1640 (Gibco, Grand Island, NY) with 10% fetal bovine serum. HBL-100, MDA-MB-231 and MDA-MB-435 were cultured in Dulbecco's modified Eagle's medium (Gibco) with 10% fetal bovine serum. Forty pairs of tumorous and adjacent non-tumorous breast tissues were collected from patients undergoing resection for breast cancer in Cancer Hospital of Tianjin Medical University. Informed consent was obtained from each patient and the study was approved by the Institutional Research Ethics Committee in Nankai University.
The siRNAs targeting human HBXIP (si-HBXIP)/cAMP response elementbinding protein (CREB) (si-CREB)/FGF8 (si-FGF8)/VEGF (si-VEGF), control siRNA (si-Control), miR-503 mimics (miR-503), negative control (NC), miR-503 inhibitor (anti-miR-503) and inhibitor negative control (anti-miR-NC) were synthesized by RiboBio (Guangzhou, China). All oligonucleotide sequences are listed in Supplementary Table 1 , available at Carcinogenesis Online. These experiments of immunohistochemistry (IHC) analysis, western blot  analysis, reverse transcription-PCR (RT-PCR), quantitative RT-PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were carried out as described previously (23, 28) . The breast cancer tissue microarrays (No. 08C14) were obtained from Xi'an Aomei Biotechnology Co., Ltd (Xi'an, China). These microarrays were composed of 49 breast cancer tissue samples and 1 normal breast tissue. For IHC analysis, tumor slides (thickness: 5-10 µm) were fixed in 4% paraformaldehyde for 2 days. Sections were stained using antibodies directed against Ki67 (Santa Cruz Biotechnology, Santa Cruz, CA) and CD31 (Abcam, Cambridge, UK). For western blot analysis, the primary antibodies were mouse anti-HBXIP (Abcam), rabbit anti-FGF8 (Proteintech Group, Chicago, IL), rabbit anti-VEGF (Proteintech Group), mouse anti-CREB (Santa Cruz), rabbit anti-Phospho-CREB (pS133) (Epitomics, Burlingame, CA), rabbit anti-HIF1α (Proteintech Group), rabbit anti-Akt (Proteintech Group), rabbit anti-phospho-Akt (Ser473) (Cell Signaling Technology, Beverly, MA) and mouse anti-β-actin (Sigma-Aldrich, St Louis, MO). Forskolin is an activator of adenylyl cyclase (Beyotime Institute of Biotechnology, Haimen, China). 8-Bromoadenosine 3′5′-cyclic monophosphate (8-Br-cAMP) is a cyclic AMP analog (Sigma-Aldrich). Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor (Santa Cruz). For RT-PCR and qRT-PCR, total RNA was extracted from the cells using Trizol reagent (Invitrogen, Carlsbad, CA). The first-strand cDNA was synthesized by PrimeScript reverse transcriptase (TaKaRa Bio, Dalian, China) following the manufacturer's instructions. The primers are listed in Supplementary Table 1, available at Carcinogenesis Online. qRT-PCR was performed using double-stranded DNA-specific SYBR Premix Ex TaqTM II Kit (TaKaRa Bio) according to the instructions of manufacturer. For ELISA, breast cancer cells were seeded in six-well plates at a density of 2 × 10 5 cells per well and treated with plasmids (or siRNAs or reagents), the conditioned media were collected after 24 h of incubation. ELISA was employed to quantitatively examine FGF8 and VEGF levels in the conditioned media, according to the manufacturer's instructions with a detection limit of 5 pg/ml.
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Luciferase reporter constructs and luciferase reporter gene assays
These experiments were carried out as described previously (23, 26, 28) . The constructs of FGF8 promoter fragment were named pGL3-FGF8-P1 (−1454/−317), pGL3-FGF8-P2 (−1294/−317), pGL3-FGF8-P3 (−1080/−317) and pGL3-FGF8-P4 (−904/−317), respectively. The mutant construct of pGL3-FGF8-P3 (termed pGL3-FGF8-P3-MUT) carried a substitution of four nucleotides within the binding sites of CREB. The construct of VEGF promoter was named pGL3-VEGF-P. Four nucleotides within the binding sites of hypoxia-inducible factor 1-alpha (HIF1α) were deleted as the mutant construct of pGL3-VEGF-P (termed pGL3-VEGF-P-ΔHRE). The 3′ untranslated regions (UTRs) of FGF8 (134 bp) and VEGF (405 bp) were subcloned into the XbaI/FseI site of the pGL3-Control vector to generate FGF8 3′UTR and VEGF 3′UTR. Mutant constructs of FGF8 and VEGF 3′UTRs were termed FGF8 3′UTR-MUT and VEGF 3′UTR-MUT. All primers are listed in Supplementary Table 1, available at Carcinogenesis Online.
Chromatin immunoprecipitation, coimmunoprecipitation, pull-down and electrophoretic mobility shift assays These experiments were described previously (23, 29) . For the chromatin immunoprecipitation assay, protein-DNA complexes were immunoprecipitated with anti-HBXIP (or anti-CREB) antibody. Normal mouse IgG was used as a negative control. For the coimmunoprecipitation assay, cells were washed three times with phosphate-buffered saline and then lysed. The lysates incubated at 4°C with respective primary antibodies for 4 h. And then the protein G beads were added and incubated for an additional 4 h. After six rounds of washes with the same lysis buffer, coprecipitated proteins were resuspended and then analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by immunoblotting. For pull-down assays, recombinant GST-tagged CREB and His-tagged HBXIP proteins were used. For the electrophoretic mobility shift assay (EMSA), nuclear extracts from MCF-7 and MCF-7-HBXIP cell lines were prepared. Oligonucleotides of the FGF8 promoter were labeled with 32 P-γATP using T4 polynucleotide kinase. The EMSA reactions were carried out as described previously (23) .
Tube formation and anchorage-independent growth assays
Tube formation, an in vitro matrigel angiogenesis assay, was performed as described previously (30) . Briefly, 24-well plates were coated with 200 µl per well growth factor-reduced matrigel (BD Biosciences, Franklin Lakes, NJ). HUVECs monolayers were nutrient starved for 4 h in serum-free RPMI 1640 medium before they were resuspended and seeded at 5 × 10 4 cells per well in the presence of conditioned media. After 6 h, images of forming capillarylike structures were captured. For anchorage-independent growth assay on soft agar, transfected MCF-7 cells (3 × 10 4 ) were seeded in six-well plates, with a bottom layer of 0.6% low-melting-temperature agar in RPMI 1640 and a top layer of 0.35% agar in RPMI 1640. The plates were incubated at 37°C and 5% CO 2 for 21 days, after that the cultures were inspected and photographed.
Tumor xenograft in mice and hemoglobin content analysis
Nude mice were housed and treated according to guidelines established by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Four-week-old female BALB/c athymic nude mice (Experiment Animal Center of Peking, China) (each group, n = 5) were subcutaneously injected with (4 × 10 5 ) MCF-7 treated with si-Control or MCF-7-HBXIP treated with si-control (or si-FGF8 or si-VEGF) cells. Tumor growth after 10 days from injection was monitored by measuring the length (L) and width (W) with calipers every 4 days. After 4 weeks, the animals were killed to remove tumors for analysis. The tumors were measured and calculated with the formula: (L × W 2 ) × 0.5. Hemoglobin concentration was determined as described previously (31) .
Statistical analysis
Values were expressed as the mean ± SD of at least three independent experiments. Statistical significance was assessed by comparing mean values (± SD) using Student's t-test. P <0.05 was considered statistically significant. FGF8 expression in breast cancer tissues and their corresponding non-tumorous tissues was analyzed using Wilcoxon signed-rank test. Pearson's correlation coefficient was used to determine the expression correlation of genes in clinical breast cancer tissues.
Results
HBXIP upregulates FGF8 in breast cancer cells and increases its secretion
Previously, we reported that HBXIP was overexpressed in clinical breast cancer tissues and was able to enhance proliferation and migration of breast cancer cells (23) (24) (25) (26) 28) . In this study, we try to explore whether HBXIP contributes to angiogenesis in breast cancer. FGF8 plays an important role in the tumorigenesis by enhancing tumor angiogenesis in prostate and breast cancers (7, 9, 10) . Accordingly, we are interested in the relationship between HBXIP and FGF8 in breast cancer. Our data showed that the positive rates of HBXIP and FGF8 were 81.6% (40/49) and 73.5% (36/49) in clinical breast cancer tissues by IHC staining using tissue microarrays, respectively (Figure 1A and Supplementary Table 2 , available at Carcinogenesis Online). Interestingly, the positive rate of FGF8 was 87.5% (35/40) in HBXIP-positive tissues. In addition, we validated that the mRNA levels of FGF8 were much higher in breast cancer tissues relative to their non-cancerous counterparts (P < 0.01, Wilcoxon signed-rank test, Supplementary Figure 1A , available at Carcinogenesis Online) (7, 8) . Additionally, qRT-PCR assays revealed that the expression levels of FGF8 were significantly correlated with those of HBXIP in five breast cancer cell lines (r = 0.996, P < 0.001, Pearson's correlation coefficient, Supplementary Figure 1B , available at Carcinogenesis Online). Thus, our data suggest that the expression levels of FGF8 are significantly associated with those of HBXIP in breast cancer tissues.
On the basis of the correlation between HBXIP and FGF8 in breast cancer tissues, we hypothesized that HBXIP might upregulate FGF8 in breast cancer cells. To investigate the effect of HBXIP on FGF8 expression, we performed overexpression or depletion of HBXIP by transfection with HBXIP plasmid or si-HBXIP in breast cancer cell lines. Our data showed that overexpression of HBXIP could remarkably upregulate FGF8 in MCF-7 cell line ( Figure 1B and Supplementary Figure 1C , available at Carcinogenesis Online). Meanwhile, the secretion levels of FGF8 were increased in the conditioned media in the system ( Figure 1C and Supplementary Figure 1D , available at Carcinogenesis Online). Conversely, depletion of HBXIP resulted in the downregulation of FGF8 in MDA-MB-231 and MCF-7-HBXIP cells in a dose-dependent manner ( Figure 1D and Supplementary Figure 1E , available at Carcinogenesis Online). Meanwhile, the secretion levels of FGF8 were decreased in the conditioned media in the system as well ( Figure 1E and Supplementary Figure 1F , available at Carcinogenesis Online).
Given that HBXIP was a coactivator of transcriptional factors in breast cancer cells (23) (24) (25) (26) , we speculated that HBXIP might upregulate FGF8 through activating the promoter of FGF8. To test this hypothesis, we constructed the fragments of human FGF8 promoter, including −1454/−317 (pGL3-FGF8-P1), −1294/−317 (pGL3-FGF8-P2), −1080/−317 (pGL3-FGF8-P3) and −904/−317 (pGL3-FGF8-P4) ( Figure 1F and Supplementary Figure 1G , available at Carcinogenesis Online). Luciferase reporter gene assays indicated that the regions of −1454/−317, −1294/−317 and −1080/−317 exhibited similar luciferase activities, which were higher than the region of −904/−317 or pGL3-Basic, indicating that the fragment −1080/−904 contains the core region of FGF8 promoter ( Figure 1F ). To investigate the effect of HBXIP on FGF8 promoter activity, we modulated the expression of HBXIP by transfection with HBXIP plasmid or si-HBXIP to measure the activities of various promoter constructs in breast cancer cells. Our results indicated that HBXIP could significantly increase (F) MCF-7 cells were cotransfected with pGL3-FGF8-P1 (or pGL3-FGF8-P2, pGL3-FGF8-P3 or pGL3-FGF8-P4) and HBXIP. The pCMV vector was used as a control. The promoter activities of FGF8 were measured by luciferase reporter gene assays. Statistically significant differences are indicated: *P < 0.05, **P < 0.01, Student's t-test. We performed separate experiment in triplicate.
the activities of FGF8 promoter and the regulation sites of HBXIP covered the region of −1080/−904 ( Figure 1F and Supplementary Figure 1H , available at Carcinogenesis Online). Thus, we conclude that HBXIP is able to upregulate FGF8 in breast cancer cells and increases its secretion.
HBXIP activates FGF8 promoter through interacting with transcriptional factor CREB
To dissect the mechanism by which HBXIP activates FGF8 promoter, we analyzed the identified core region of −1080/−904 by bioinformatics using Genomatix software suite. Interestingly, we observed that the region contained several transcriptional factor-binding sites, such as CREB, c-Myc and MZF1, etc. HBXIP is essential for CREB-dependent transcriptional activity of HBx (32), therefore, we wonder whether HBXIP activates FGF8 promoter through CREB.
As expected, the promoter activity of FGF8 could be abolished by si-CREB in MCF-7-HBXIP and MDA-MB-231 cells (Figure 2A) . Moreover, we showed that HBXIP failed to work when the CREBbinding site was mutated in FGF8 promoter ( Figure 2B ). Next, we are interested in whether FGF8 is cAMP responsive. Our data showed that the level of CREB phosphorylation was increased in the forskolin (an activator of adenylyl cyclase)-treated cells, but the promoter activity of FGF8 exhibited no response to the treatment (Supplementary Figure 2A and B, available at Carcinogenesis Online). In addition, we observed the similar results in the cells treated with 8-Br-cAMP (data not shown), suggesting that FGF8 is not regulated by cAMP. To test whether HBXIP binds to FGF8 promoter via CREB, we examined the interaction of HBXIP with the region of FGF8 promoter by chromatin immunoprecipitation assay. Our data showed that HBXIP and CREB could bind to FGF8 promoter, but both of them failed to work when the cells were treated with si-CREB ( Figure 2C ), suggesting that HBXIP may bind to FGF8 promoter through interacting with CREB. Then, coimmunoprecipitation and pull-down assays indicated that HBXIP was able to directly bind to CREB in the cells ( Figure 2D and E). EMSA showed that the nuclear proteins were able to interact with 32 P-labeled CRE oligonucleotide and the band was enhanced by HBXIP ( Figure 2F ). In contrast, incubation with an unlabeled oligonucleotide decreased the specific binding of nuclear protein to the 32 P-labeled CRE oligonucleotide. Moreover, the supershift band was observed when the anti-HBXIP or anti-CREB antibody was added into the system (Figure 2F and G) . It suggests that HBXIP is a coactivator of CREB in regulation of FGF8 promoter. Thus, our data support the notion that HBXIP is capable of activating FGF8 promoter through CREB in breast cancer cells.
HBXIP upregulates FGF8 through inhibiting miR-503
To further identify other mechanisms by which HBXIP upregulates FGF8, we predicted the miRNAs targeting FGF8 by TargetScan (http://www.targetscan.org). Interestingly, we observed that there was a target site of miR-503, an antiangiogenic agent, in the 3′UTR of FGF8. Then, we examined the effect of HBXIP on miR-503 expression in breast cancer cells. As shown in Figure 3A , overexpression of HBXIP suppressed miR-503 expression in MCF-7 cells, conversely, knockdown of HBXIP resulted in the increase of miR-503 in MCF-7-HBXIP cells in a dose-dependent manner. Moreover, we found that the expression levels of miR-503 were negatively correlated with those of FGF8 in clinical breast cancer tissues by qRT-PCR analysis (r = −0.671, P < 0.01, Pearson's correlation coefficient, Figure 3B ). To ascertain whether FGF8 was one of the targets of miR-503, we cloned the 3′UTR of FGF8 mRNA and its mutant into the pGL3-Control vector, respectively ( Figure 3C ). Luciferase reporter gene assays elucidated that miR-503 could remarkably decrease the luciferase activity of FGF8 3′UTR in MCF-7-HBXIP cells. However, it failed to work when the miR-503-targeting site of FGF8 3′UTR was mutated ( Figure 3D) . Meanwhile, the anti-miR-503 was capable of increasing the luciferase activity of FGF8 3′UTR in MCF-7 cells, but the enhancement could be attenuated when the target site of miR-503 was mutated ( Figure 3E ). Subsequently, we observed that miR-503 was able to downregulate FGF8 in MCF-7-HBXIP cells, but anti-miR-503 resulted in upregulation of FGF8 in MCF-7 cells (Figure 3F and G) . Therefore, our data suggest that HBXIP is able to upregulate FGF8 through inhibiting miR-503 in breast cancer cells.
HBXIP-induced FGF8 upregulates VEGF through activating PI3K/Akt/HIF1α signaling in breast cancer cells and increases its secretion
It has been reported that VEGF is one of the best known angiogenic factors and miR-503 is able to target VEGF in hepatoma cells (33) . Therefore, we are interested in whether HBXIP upregulates VEGF through suppressing miR-503 in breast cancer cells. We found that the expression levels of miR-503 were inversely correlated with those of VEGF in clinical breast cancer tissues. Then, we demonstrated that miR-503 downregulated VEGF through directly targeting its 3′UTR in breast cancer cells (Supplementary Figure 3A- F, available at Carcinogenesis Online). Accordingly, we examined the expression relationship between HBXIP and VEGF in clinical breast cancer tissues. We found that the positive rate of VEGF was 80.0% (32/40) in HBXIP-positive tissues by IHC staining analysis (Figure 4A and  Supplementary Table 2 ). Moreover, we demonstrated that HBXIP was able to upregulate VEGF expression in MCF-7 cells in a dosedependent manner ( Figure 4B) . Meanwhile, the secretion levels of VEGF were remarkably increased in the media of HBXIP-transfected MCF-7 cells ( Figure 4C ). Thus, our data suggest that HBXIP upregulates VEGF through downregulating miR-503 in breast cancer cells and increases its secretion.
Given that FGF2 could influence VEGF expression through PI3K/Akt/HIF1α signaling (14), we concerned about whether HBXIP-induced FGF8 was involved in the upregulation of VEGF in breast cancer. Interestingly, we showed that the expression levels of VEGF mRNA were positively correlated with those of FGF8 in clinical breast cancer tissues (r = 0.84, P < 0.001, Pearson's correlation coefficient, Figure 4D ). Moreover, we found that depletion of FGF8 reduced the upregulation of VEGF mediated by HBXIP in MCF-7-HBXIP cells and MCF-7 cells transiently transfected with HBXIP ( Figure 4E ), suggesting that HBXIP-induced FGF8 is able to upregulate VEGF in breast cancer cells.
It has been reported that HIF1 is overexpressed in primary breast cancer and FGF8 could activate PI3K/Akt signaling (34, 35) . Accordingly, we supposed that the PI3K/Akt/HIF1α signaling might be responsible for the upregulation of VEGF mediated by HBXIP-elevated FGF8 in the cells. As expected, our data showed that the upregulation of p-Akt, HIF1α and VEGF mediated by HBXIP could be significantly reduced when the cells were treated with PI3K inhibitor or anti-FGF8 antibody ( Figure 4F ). In addition, we constructed the VEGF promoter containing a reported HRE site (36) . Interestingly, we found that overexpression of HBXIP was able to increase the promoter activity of VEGF. Conversely, the effect could be abrogated when the HRE site was mutated. Moreover, the enhancement of VEGF promoter activity mediated by HBXIP could be reduced by PI3K inhibitor or si-FGF8 (Supplementary Figure 4A and B, available at Carcinogenesis Online). Meanwhile, the HBXIP-enhanced VEGF secretion was abrogated in the conditioned media in the system ( Figure 4G ). Therefore, we conclude that HBXIP-induced FGF8 is able to upregulate VEGF through activating PI3K/Akt/HIF1α signaling in breast cancer cells and increases its secretion.
HBXIP promotes angiogenesis and cell proliferation in breast cancer through FGF8 and VEGF in vitro
To determine the role of HBXIP in angiogenesis in breast cancer through FGF8 and VEGF, we performed matrigel angiogenesis assays using the conditioned media from HBXIP-overexpressing MCF-7 cells. Our data showed that the formation of capillary-like structures was increased when the HUVECs were cultured in 70% (vol/vol) conditioned media from HBXIP-transfected MCF-7 cells relative to control ( Figure 5A) . Meanwhile, the neutralization of FGF8 (or VEGF) activity in the conditioned media from HBXIP-transfected MCF-7 cells by anti-FGF8 (or anti-VEGF) antibody resulted in a significant reduction of formation of capillary-like structures ( Figure 5A ), suggesting that HBXIP promotes tumor angiogenesis through FGF8 and VEGF. Furthermore, we tested whether HBXIP enhanced proliferation of MCF-7 cells through FGF8 or VEGF by colony formation and MTT assays. Interestingly, we found that the enhancement of cell proliferation mediated by HBXIP could be abolished by si-FGF8 or si-VEGF ( Figure 5B and C and Supplementary Figure 5A and B, available at Carcinogenesis Online). Therefore, our data suggest that HBXIP promotes angiogenesis and cell proliferation in breast cancer through FGF8 and VEGF in vitro.
HBXIP increases angiogenesis and growth of breast cancer in vivo
To better understand the contribution of HBXIP to tumor angiogenesis and growth, we performed tumor xenograft analysis. Figure 6A -C and Supplementary Figure 6 , available at Carcinogenesis Online, showed that overexpression of HBXIP enhanced the tumor growth in mice transplanted with MCF-7 cells, while the enhanced growth could be attenuated by knockdown of FGF8 or VEGF. The formation of neovessels in tumor tissues was determined by the presence of red blood cells and mouse endothelial cells. As shown in Figure 6D , the hemoglobin content in tumor tissues derived from MCF-7-HBXIP cells was 1-fold higher than that in the tissues derived from control cells. Consistent with the results of the hemoglobin content measurement, we found that the tumor tissues derived from MCF-7-HBXIP cells were much more intensively vascularized relative to controls as determined by more intense staining of the marker CD31 ( Figure 6E ), suggesting that overexpression of HBXIP is intimately associated with the presence of a higher density of vasculature and endothelial cells in the tumor tissues as xenografts. Meanwhile, knockdown of FGF8 or VEGF remarkably reduced the HBXIP-enhanced hemoglobin content and CD31 in tumor tissues ( Figure 6D and E) . Besides, the Ki67 staining supported that overexpression of HBXIP was able to promote proliferation of MCF-7 cells. However, downregulation of FGF8 (or VEGF) by si-FGF8 (or si-VEGF) could block the HBXIP-enhanced proliferation of breast cancer cells in tumor tissues, suggesting that HBXIP can promote proliferation of breast cancer cells through FGF8 and VEGF in tumor tissues ( Figure 6F ). Taken together, our data suggest that HBXIP promotes tumor angiogenesis and growth of breast cancer through FGF8 and VEGF in vivo. Wortmannin is the inhibitor of PI3K. Statistically significant differences are indicated: *P < 0.05, **P < 0.01, Student's t-test. We performed separate experiment in triplicate.
Discussion
Tumor angiogenesis plays a vital role in the development of cancer. FGF and VEGF families are the most potent promoters of angiogenesis. Numerous reports have demonstrated that dysregulation of FGF-FGF receptor and VEGF-VEGF receptor signaling, whatever it is at the ligand and/or receptor level, is able to result in tumor development and progression (2, 3, 13, 15, 17) . Recently, we have reported that the oncoprotein HBXIP significantly promotes proliferation and migration of breast cancer cells through upregulating S100A4, LMO4, Skp2 and Lin28B (23) (24) (25) (26) . In this study, we are interested in the role of HBXIP in angiogenesis in breast cancer.
It has been reported that the mammalian FGF family comprises 18 ligands, which exert their actions through 4 highly conserved transmembrane tyrosine kinase receptors (3) . The high frequency of FGF8 expression is detected in the clinical breast cancer tissues, which increases tumor growth, invasion and angiogenesis (7-9); however, its regulatory mechanism is poorly understood. In this study, we showed that the positive rate of FGF8 expression was 73.5% in clinical breast cancer tissues. Interestingly, we found that the positive rate of FGF8 was 87.5% (35/40) in HBXIP-positive breast cancer tissues. Moreover, our data showed that HBXIP was able to upregulate FGF8 in breast cancer cells. Our previous studies showed that HBXIP acted as a coactivator of transcriptional factor (23) (24) (25) (26) . Accordingly, we identified that HBXIP was capable of activating FGF8 promoter through directly interacting with transcriptional factor CREB, suggesting that HBXIP upregulates FGF8 through acting as a coactivator of CREB. Previous studies showed that CREB was able to activate the promoters of BRCA1 and bcl-2, which were not stimulated by forskolin (37, 38) . Oct-1 potentiated CREB-dependent cyclin D1 transcriptional activity via a phospho-CREB and CBP-independent mechanism (39) . In this study, we found that FGF8 was not regulated by cAMP. That may be due to lack of canonical TATA box near the CREB-binding sites, which is essential for cAMP responsiveness (40) .
As we know, microRNAs are small non-coding RNAs that can act as oncogenes or tumor suppressor genes in human cancers. We further investigated the mechanism by which HBXIP upregulated FGF8 at the posttranscriptional level. Interestingly, we observed that the miR-503-binding site existed in 3′UTR of FGF8. A growing number of studies have proposed that miR-503 might be a master regulator of the cell cycle, metastasis and angiogenesis (41, 42) . We found that HBXIP was able to suppress miR-503 expression in breast cancer cells. Indeed, we showed that FGF8 was one of the target genes of miR-503. Recent study has reported that hypermethylation of the miR-503 CpG island regions is associated with downregulation of miR-503 (33). We previously found that overexpression of HBXIP significantly elevated DNA (cytosine-5-)-methyltransferase 1 (DNMT1) levels in MCF-7 cells (23) . It suggests that HBXIP may suppress miR-503 expression via epigenetic modulation of its promoter. Moreover, we validated that VEGF was another target gene of miR-503 in breast cancer cells as well. This finding is consistent with the report that miR-503 is able to target VEGF in hepatoma cells (33) . Next, we demonstrated that HBXIP upregulated VEGF through suppressing miR-503 in breast cancer cells. Taken together, our finding provides evidence that HBXIP upregulates both FGF8 and VEGF through suppressing miR-503 in breast cancer cells.
Emerging evidence shows that FGF2 induces VEGF expression to promote tumor angiogenesis (14, 43) . Therefore, we are interested in whether FGF8 regulates VEGF in breast cancer cells. Strikingly, we revealed that HBXIP-induced FGF8 was able to upregulate VEGF through activating PI3K/Akt/HIF1α signaling. It is well established that tumor growth is angiogenesis-dependent and FGFs may play an integral role in resistance to anti-VEGF therapy (2, 17) . Dual blockade of FGF and VEGF signaling are currently being evaluated in clinical trials. In this study, we found that HBXIP strongly increased both expression and secretion of FGF8 and VEGF, resulting in tumor angiogenesis and growth of breast cancer in vitro and in vivo.
We added more information involving our previous papers and other reports (44) (45) (46) (47) (48) (49) (50) in Supplementary Figure 7 , available at Carcinogenesis Online. In this model, we show that HBXIP plays an important role in regulation of tumor angiogenesis and growth in a network manner, in which FGF8 may influence Lin28B (or LMO4, S100A4) through PI3K/Akt signaling (23,46,48,49) ; Lin28B may enhance FGF8 signaling through inhibiting let-7, which targets FGF receptor (48, 50) ; LMO4 may increase VEGF expression via downregulating p53, which reduces HIF1α expression (45, 47) ; S100A4 can upregulate VEGF expression (44) . Collectively, HBXIP plays a vital role in the development of breast cancer. Therapeutically, HBXIP may serve as a novel target of tumor angiogenesis.
In summary, the central finding of this work is that HBXIP can remarkably induce tumor angiogenesis and growth through upregulating the expression and secretion of FGF8 and VEGF in breast cancer. HBXIP is able to activate FGF8 promoter through directly interacting with CREB. In addition, HBXIP upregulates FGF8 and VEGF through suppressing miR-503. Interestingly, HBXIP-enhanced FGF8 stimulates VEGF expression via activating PI3K/Akt/HIF1α signaling. Thus, our finding provides new insights into the mechanism of tumor angiogenesis and growth of breast cancer.
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